A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma
| Autor: | Howard W Bruckner, Magdalena Petryk, Peter Kozuch |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
medicine.medical_specialty Palliative care Organoplatinum Compounds Paclitaxel medicine.medical_treatment Leucovorin Antineoplastic Agents Docetaxel Adenocarcinoma Interferon alpha-2 Irinotecan Deoxycytidine Targeted therapy Clinical Trials Phase II as Topic Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Multicenter Studies as Topic Enzyme Inhibitors Bone Marrow Diseases Epirubicin Respiratory Distress Syndrome business.industry Standard treatment Palliative Care Interferon-alpha Combination chemotherapy Hematology Metastatic Pancreatic Adenocarcinoma Gemcitabine Recombinant Proteins Surgery Clinical trial Pancreatic Neoplasms Treatment Outcome Clinical Trials Phase III as Topic Hemolytic-Uremic Syndrome Camptothecin Taxoids Fluorouracil business medicine.drug |
| Zdroj: | Hematology/oncology clinics of North America. 16(1) |
| ISSN: | 0889-8588 |
| Popis: | Phase II trials of combination chemotherapies have shown encouraging palliative benefit, objective response rates, and survival outcomes. Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine. The fixed rate infusion schedule of 10 mg/m2/min is gaining wide acceptance and is a promising investigational priority. A very reasonable alternative to single agent gemcitabine, and our bias, is enrollment into clinical trials evaluating novel gemcitabine-based combinations. Further investigation is needed to determine optimal incorporation of so-called targeted therapy with combination chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|